 fate aggregated immunoglobulin IgA nephropathy patients healthy controls Organ uptake IgA-containing active material humans intravenous IV injection heat-aggregated human secretory IgA HAS-IgA patients primary IgA nephropathy normal volunteers Aggregated secretory IgA liver peak activity liver minutes range minutes patients minutes range minutes controls rate increase liver radioactivity patients mean slope range mean liver ratio peak time patients mean value range controls mean value range data pivotal role liver removal aggregated IgA humans defective clearance capacity test probe IgA nephropathy patients